[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519988":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":22,"locations":28,"responsibleParty":106,"collaborators":108,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":7,"enrollmentInfo":120,"targetDuration":7,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":7,"overallStatus":76,"whyStopped":7,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",null,[9,13,16,19],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Radiotherapy - Low risk group","20 fractions completed in 4 weeks",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Radiotherapy - Standard risk group","25 fractions completed in 5 weeks",{"type":10,"name":17,"description":18,"armGroupLabels":7,"otherNames":7},"Radiotherapy - Intermediate risk group","30 fractions completed in 6 weeks",{"type":10,"name":20,"description":21,"armGroupLabels":7,"otherNames":7},"Radiotherapy - High risk group","35 fractions completed in 7 weeks",[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Ali Hosni","CONTACT","416-946-2360","ali.hosni@uhn.ca",[29,46,59,74,91],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Allegheny Health Network","NOT_YET_RECRUITING","Pittsburgh","Pennsylvania","15212","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-79.99589,40.44062,{"lat":41,"lon":40},[44],{"name":45,"role":25,"phone":7,"phoneExt":7,"email":7},"Alexander Kirichenko, MD",{"facility":47,"status":31,"city":48,"state":49,"zip":50,"country":35,"countryCode":36,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Medical College of Wisconsin Cancer Center","Milwaukee","Wisconsin","53226",{"type":38,"coordinates":52},[53,54],-87.90647,43.0389,{"lat":54,"lon":53},[57],{"name":58,"role":25,"phone":7,"phoneExt":7,"email":7},"William A Hall, MD",{"facility":60,"status":31,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Austin Health","Heidelberg","Victoria","3084","Australia","AU",{"type":38,"coordinates":67},[68,69],145.06667,-37.75,{"lat":69,"lon":68},[72],{"name":73,"role":25,"phone":7,"phoneExt":7,"email":7},"Ee Siang Choong, MD",{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2C1","Canada","CA",{"type":38,"coordinates":83},[84,85],-79.39864,43.70643,{"lat":85,"lon":84},[88],{"name":89,"role":25,"phone":26,"phoneExt":7,"email":90},"Ali Hosni, MD","ali.hosni.abdalaty@rmp.uhn.ca",{"facility":92,"status":31,"city":93,"state":94,"zip":95,"country":80,"countryCode":81,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"CHUM - Centre hospitalier de l'Université de Montréal","Montreal","Quebec","H2X 0C1",{"type":38,"coordinates":97},[98,99],-73.58781,45.50884,{"lat":99,"lon":98},[102],{"name":103,"role":25,"phone":104,"phoneExt":7,"email":105},"Mame Daro Faye, MD","514 890-8254","mame.daro.faye.med@ssss.gouv.qc.ca",{"type":107,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[109],{"name":110,"class":6},"Medical College of Wisconsin","100519988","phase-2-mr-adaptive-radiation-therapy-for-anal-cancer-with-escalated-treatment-in-a-risk-optimized-approach-100519988",false,"NCT06050707","MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach","MAESTRO","Inclusion Criteria:\n\n* Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible.\n* Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) \u002F the American Joint Committee on Cancer (AJCC) 8th Ed)\n* Patients must be eligible for definitive RT or CRT\n* Must be ≥ 18 years of age\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer.\n* Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.\n* Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.","ALL","18 Years",{"count":121,"type":122},80,"ESTIMATED","INTERVENTIONAL",[125],"PHASE2","The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.",[128],"Anal Squamous Cell Carcinoma","2026-06-09",{"date":131,"type":132},"2026-06-10","ACTUAL",{"date":134,"type":132},"2023-09-29",{"date":136,"type":122},"2028-09-01",{"name":5,"class":6},5]